Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Erasca, Inc.
  6. News
  7. Summary
    ERAS   US29479A1088

ERASCA, INC.

(ERAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference

11/16/2021 | 08:01am EST

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Evercore ISI 4th Annual HealthCONx Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a “Fireside Chat” beginning at 3:05 PM Eastern Time on Thursday, December 2, 2021. The company will also participate in one-on-one investor meetings.

Registration and access to the live webcast is available at Evercore.webcasts. An archived replay of the event will be available at Erasca.com/events for 30 days following the webcast.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com


Primary Logo

Source: Erasca, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about ERASCA, INC.
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca Strengthens Leadership Team with Two Key Executive Appointments
GL
01/18Erasca, Inc. Announces Executive Changes
CI
01/12Certain Stock Options of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-J..
CI
01/12Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-JA..
CI
01/04Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03Guggenheim Adjusts Price Target for Erasca to $20 From $25, Maintains Buy Rating
MT
2021ERASCA, INC.(NASDAQGS : ERAS) added to S&P Global BMI Index
CI
2021ERASCA, INC.(NASDAQGS : ERAS) added to NASDAQ Biotechnology Index
CI
2021Erasca Wins US FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme
MT
More news
Analyst Recommendations on ERASCA, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -133 M - -
Net cash 2021 103 M - -
P/E ratio 2021 -5,14x
Yield 2021 -
Capitalization 1 438 M 1 438 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 102
Free-Float -
Chart ERASCA, INC.
Duration : Period :
Erasca, Inc. Technical Analysis Chart | ERAS | US29479A1088 | MarketScreener
Technical analysis trends ERASCA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 11,86 $
Average target price 29,80 $
Spread / Average Target 151%
EPS Revisions
Managers and Directors
Jonathan E. Lim Chairman & Chief Executive Officer
David M. Chacko Chief Business Officer
Michael D. Varney Chairman-Research & Development
Wei Lin Chief Medical Officer
Nik Chetwyn Senior Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ERASCA, INC.-23.88%1 438
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381